Zai Lab Announces Primary Listing on the Main Board of The Stock Exchange of Hong Kong Limited

2022年 6月 27日

Read More

Zai Lab Announces Breakthrough Therapy Designations Granted for Repotrectinib in China

2022年 6月 10日

Read More

Zai Lab and Novocure Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer

2022年 6月 03日

Read More

Zai Lab’s Updated Statement on SEC Listing Matter

2022年 6月 01日

Read More

Zai Lab to Present New PRIME Subgroup Analysis for Niraparib in Ovarian Cancer at 2022 ASCO Annual Conference

2022年 5月 31日

Read More

Zai Lab Announces Upcoming Presentations at June Investor Conferences

2022年 5月 24日

Read More

再鼎醫藥公佈2022年第一季度財務業績和公司進展

2022年 5月 10日

Read More

Zai Lab Partner argenx Announces Positive Phase 3 Data from ADVANCE Trial of VYVGART® (efgartigimod alfa-fcab) in Adults with Primary Immune Thrombocytopenia

2022年 5月 05日

Read More